{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 141,
  "pageCount": 366,
  "prevPage": 140,
  "nextPage": 142,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses direct citations from peer-reviewed papers to validate the consultant's findings.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/141",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-141",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "pitolisant is a “potent inhibitor of CYP2D6 and hERG”; “our laboratory findings suggest that CYP2D6 inhibition...would likely be important hurdles for this novel compound”; and that “in vitro profiling in our laboratory (and others) suggests that BF2.639 [pitolisant] has both a CYP2D6 liability...and potent hERG channel K+ blockade.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd4-bb41cb832ef2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "list",
      "text": "2010 review paper, Raddatz et al; 2008 paper by Abbott scientists; 2009 paper by Evotec scientists",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "badfd341-89a7-44ba-8483-5b3c93e6985b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The CYP2D6 concerns voiced by our pharmacology consultant are consistent with the scientific literature on problems with H3 reception antagonists/inverse agonists, particularly ones with the same non-imidazole structure as pitolisant, as we discussed in a previous section. We further noted papers by pharma companies like Abbott and Evotec which synthesized pitolisant and concluded that it is plagued by severe problems including cardiotoxicity and CYP2D6 issues, and who also indicated that Bioprojet’s claims were not reproducible in their labs. We again excerpt some of those papers here: pitolisant is a “potent inhibitor of CYP2D6 and hERG”; “our laboratory findings suggest that CYP2D6 inhibition...would likely be important hurdles for this novel compound”; and that “in vitro profiling in our laboratory (and others) suggests that BF2.639 [pitolisant] has both a CYP2D6 liability...and potent hERG channel K+ blockade.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa5a869f-bc92-4d22-a96a-871416ab813a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“potent inhibitor of CYP2D6 and hERG” — Raddatz et al. “our laboratory findings suggest that CYP2D6 inhibition...would likely be important hurdles for this novel compound” — Abbott scientists. “in vitro profiling in our laboratory (and others) suggests that BF2.639 [pitolisant] has both a CYP2D6 liability...and potent hERG channel K+ blockade.” — Evotec scientists.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd4-bd2031127e54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: https://pubmed.ncbi.nlm.nih.gov/20166960/; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483387/pdf/bjp2008147a.pdf; https://pubmed.ncbi.nlm.nih.gov/19429511/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce2e2a73-03ad-4920-baed-a08c5cc307b5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "3aab6820-05ed-4e3d-bb2f-2f26c106b318",
      "evidence": "Citing scientific literature to validate consultant claims",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}